Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 50%Very low 1 · 25%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Prostagladin/prostacyclin analogues vs placebo

Adverse events (6 weeks' · primary Raynaud's phenomenon

Prostagladin/prostacyclin analogues may leads to higher adverse events (6 weeks' compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.59 [1.05, 2.42]
1 study · 125 participants
Low

Nitrate/nitrate derivatives vs placebo

Adverse events (3 weeks' · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs placebo

Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon

It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.54 [0.89, 2.66]
1 study · 41 participants
Very low

Alpha‐blockers vs placebo

Adverse events (4 weeks' to 180 days' · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
GRADE not reported